Onward Therapeutics SA
Description
Onward Therapeutics is a clinical stage oncology company focused on the identification and development of innovative medicines for the treatment of cancer. Our team are seasoned professionals with multiple track records in drug development and approvals, as well as licensing transactions and successful IPO. We are located at Biopôle, a life sciences campus in Epalinges near Lausanne, Switzerland, we have an affiliate in Paris, France, and also operate from Taipei, Taiwan.
Since 2021, we have acquired licenses for potential development candidates and invested in partners with transformative technology platforms. Our pipeline includes 3 multimodal programs in immuno-oncology and onco-metabolism, including:
1. OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints in a Phase 1 study
2. OT-C001, an off-the-shelf NK cell therapy in combination with mAbs under IMPD regulatory review for a Phase 1 study
3. OT-S00X, a first-in-class small molecule program in collaboration with Institut du Cancer de Montpellier (ICM) in onco-metabolism. Two leads have been identified.
We have raised a total of CHF 75.5 million (~ USD 85 million) and are currently in our Series B financing round to in-license/acquire new programs and develop the two candidates in the clinic.
Company members
Dr. C. Grace Yeh, Chairman and CEO Dr. Alain Herrera. CMO Dr. Armand de Gramont, CSO Patrick Nielly, COO
